A CB2 agonist relieved nerve pain in mice even without CB1 receptors, working through anti-inflammatory pathways
The CB2 receptor agonist AM1710 reversed neuropathic pain in mice regardless of whether they had CB1 receptors, working by reducing inflammatory cytokines and increasing the anti-inflammatory cytokine IL-10 in the spinal cord.
Quick Facts
What This Study Found
AM1710 reversed mechanical allodynia to sham levels in CB1 knockout, heterozygous, and wildtype mice via both peripheral (i.p.) and spinal (i.t.) routes. Spinal AM1710 restored IL-10 immunoreactivity in dorsal root ganglia and spinal cord, and reduced pro-inflammatory cytokines. In cell cultures, AM1710 suppressed TNF-alpha production by macrophages.
Key Numbers
AM1710 reversed allodynia to sham levels across all three CB1 genotypes. IL-10 was restored by intrathecal administration. Pro-inflammatory cytokines were reduced in spinal cord (i.t. only) and DRG (both i.p. and i.t.).
How They Did This
Chronic constriction injury model of neuropathic pain in CB1 receptor knockout, heterozygous, and wildtype mice. AM1710 administered intraperitoneally or intrathecally. Immunoreactivity for IL-10 and pro-inflammatory cytokines measured in spinal cord and dorsal root ganglia. Macrophage cultures used for in vitro validation.
Why This Research Matters
CB2 agonists that work independently of CB1 could provide pain relief without the psychoactive effects, euphoria, or abuse potential associated with CB1 activation, addressing a major limitation of current cannabinoid therapies.
The Bigger Picture
Separating pain-relieving cannabinoid effects from psychoactive ones is a central goal of cannabinoid pharmacology. This study strengthens the case for CB2 as a standalone therapeutic target for neuropathic pain.
What This Study Doesn't Tell Us
Mouse model of neuropathic pain may not fully represent human conditions. Knockout mice may develop compensatory mechanisms. Only one CB2 agonist tested. Long-term effects and tolerance were not assessed.
Questions This Raises
- ?Would CB2 agonists be effective for other types of pain beyond neuropathic?
- ?Could IL-10 elevation be a biomarker for CB2 agonist efficacy?
- ?How close are CB2-selective agonists to clinical trials for pain?
Trust & Context
- Key Stat:
- CB2 agonist reversed pain equally in CB1 knockout and wildtype mice
- Evidence Grade:
- Well-controlled preclinical study using genetic and pharmacological approaches across multiple mouse genotypes, but animal model limitations apply.
- Study Age:
- 2020 animal study. Supports ongoing development of CB2-selective agonists for pain without psychoactive effects.
- Original Title:
- Peripheral versus central mechanisms of the cannabinoid type 2 receptor agonist AM1710 in a mouse model of neuropathic pain.
- Published In:
- Brain and behavior, 10(12), e01850 (2020)
- Authors:
- Wilkerson, Jenny L(5), Alberti, Lauren B, Kerwin, Audra A, Ledent, Catherine A, Thakur, Ganesh A, Makriyannis, Alexandros, Milligan, Erin D
- Database ID:
- RTHC-02914
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why does it matter that AM1710 works without CB1?
CB1 receptors mediate the psychoactive "high" from cannabis. A drug that relieves pain through CB2 alone could provide cannabinoid-based pain relief without intoxication, euphoria, or abuse potential.
What is IL-10?
Interleukin-10 (IL-10) is an anti-inflammatory cytokine that helps resolve inflammation. This study found that the CB2 agonist boosted IL-10 in areas involved in pain processing, suggesting an anti-inflammatory mechanism for pain relief.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02914APA
Wilkerson, Jenny L; Alberti, Lauren B; Kerwin, Audra A; Ledent, Catherine A; Thakur, Ganesh A; Makriyannis, Alexandros; Milligan, Erin D. (2020). Peripheral versus central mechanisms of the cannabinoid type 2 receptor agonist AM1710 in a mouse model of neuropathic pain.. Brain and behavior, 10(12), e01850. https://doi.org/10.1002/brb3.1850
MLA
Wilkerson, Jenny L, et al. "Peripheral versus central mechanisms of the cannabinoid type 2 receptor agonist AM1710 in a mouse model of neuropathic pain.." Brain and behavior, 2020. https://doi.org/10.1002/brb3.1850
RethinkTHC
RethinkTHC Research Database. "Peripheral versus central mechanisms of the cannabinoid type..." RTHC-02914. Retrieved from https://rethinkthc.com/research/wilkerson-2020-peripheral-versus-central-mechanisms
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.